IDH2 and acute myeloid leukemia: Enasidenib (Idhifa; Celgene Corporation, Summit, NJ, USA), a small‐molecule inhibitor of mutated IDH2, was approved by the FDA in 2017 for the treatment of adults with relapsed/refractory IDH2‐mutated AML based on results of a phase 1/2 trial of enasidenib monotherapy.